lefitolimod (MGN1703) / Feng Biosciences, iPharma, Gilead 
Welcome,         Profile    Billing    Logout  
 22 Diseases   2 Trials   2 Trials   109 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lefitolimod (MGN1703) / Feng Biosciences, iPharma, Gilead
TITAN, NCT03837756 / 2018-001165-16: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Completed
2a
47
Europe, US, RoW
Saline, Lefitolimod, MGN1703, 3BNC117 and 10-1074, RUhumab-001 and RUhumab-002
University of Aarhus, Aalborg University Hospital, Odense University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, The Peter Doherty Institute for Infection and Immunity, University of Utah, Oslo University Hospital
HIV-1-infection
07/22
05/23
NCT02532205: A Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Not yet recruiting
1
60
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma, Advanced Solid Malignancies
12/18
 
NCT02668770: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Checkmark Enrollment completion of P1 combinational trial with ipilimumab
Jul 2020 - Jul 2020: Enrollment completion of P1 combinational trial with ipilimumab
Hourglass Jan 2019 - Dec 2019 : In combination with Yervoy for advanced solid malignances
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Hourglass Sep 2018 - Dec 2018 : Completion of dose escalation portion of P1 trial for advanced solid malignancies
More
Active, not recruiting
1
28
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma
05/25
05/25

Download Options